Results 131 to 140 of about 64,512 (289)

The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma Cells

Cancer Management and Research, 2020
Mei Zeng,1,* Yuhua Chen,2,* Xintao Jia,2 Yan Liu2 1Pathology Teaching and Research Section, Xiangyang Polytechnic, Xiangyang 441021, Hubei, People’s Republic of China; 2Department of Pathology, Xiangyang Central Hospital, Affiliated Hospital of ...
Zeng M, Chen Y, Jia X, Liu Y
doaj  

Stimuli‐responsive nanostructured hydrogen sulfide donors for enhanced cancer treatments

Smart Molecules, EarlyView.
Three typical kinds of stimuli‐responsive nanostructured hydrogen sulfide (H2S) donors are reviewed. The nanostructures ensure precise delivery of H2S to the lesion site and regulate the release behavior. The H2S‐based gas therapy has been used to synergize with other cancer treatment modalities, achieving enhanced efficacy while reducing side effects.
Yuxuan Lyu, Jiaxuan Zhu, Lei Lei, Qingyang Zhong, Zhao Li, Caihong Lei, Fan Rong, Yin Wang   +7 more
wiley   +1 more source

Mapping of the interaction domains between MDM2 and ORF50, and ubiquitination of ORF50 by MDM2 in vitro.

, 2016
(A) Defining the ORF50-interacting domain of MDM2. The purified His-tagged ORF50 (His-ORF50) was incubated with GST, GST-MDM2 or GST-MDM2 deletion mutants (1–220, 100–290 and 221–491) expressed in E. coli.
Ying-Ju Shih (3188985), Li-Kwan Chang (12818), Tzu-Hsuan Chang (1847365), Lee-Wen Chen (3188979), Shih-Tung Liu (12823), Shie-Shan Wang (3188982), Pey-Jium Chang (479322)   +6 more
core   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source

Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition

BMC Cancer
Purpose The human double minute 2 homolog hdm2, alias mdm2, is the main negative-regulator of the tumor suppressor p53. In that capacity, mdm2 is a promising but not yet utilized molecular target for the treatment of breast cancer, however, its ...
Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff   +5 more
doaj   +1 more source

CENPN contributes to pancreatic carcinoma progression through the MDM2-mediated p53 signaling pathway

Archives of Medical Science
Introduction We undertook an in-depth investigation of the data pertaining to pancreatic adenocarcinoma (PAAD) to identify potential targets for the development of precision therapies.
Ming Xu, Jie Tang, Qiong Sun, Jing Meng, Guoyu Chen, Yunli Chang, Yao Yao, Jieru Ji, Hao Luo, Lingling Chen, Minxue Lu, Weiwei Shi   +11 more
doaj   +1 more source

S3: Evolution of MDM2 and TP53 status over time of 5 patients affected by MDM2-amplified GBM. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

, 2016
S3: Evolution of MDM2 and TP53 status over time of 5 patients affected by MDM2-amplified GBM.
Kristine Pelton (153505), Keith L. Ligon (9122093), Marianne Labussière (842441), Yannick Marie (267995), Charlotte Schmitt (90337), Patrick Y. Wen (14878811), Brian M. Alexander (4598146), Camille Levasseur (14995119), Karima Mokhtari (128002), Azra H. Ligon (9122087), Jeremy Guehennec (14995122), Khê Hoang-Xuan (268004), Marc Sanson (268012), Jean-Yves Delattre (128133), Samer Haidar (14995116), David Knoff (14995125), Lauriane Goldwirt (14995113), Ahmed Idbaih (127985), Maite Verreault (390193)   +18 more
core   +1 more source

LINC00892 inhibits hepatocellular carcinoma progression through SBDS/EIF6‐mediated ribosomal stress and interacting with the immune microenvironment

VIEW, EarlyView.
LINC00892 is lowly expressed in HCC. LINC00892 overexpression induces ribosomal stress via inhibiting SBDS, restrains EIF6 nuclear translocation and activates p53 pathway. LINC00892 overexpression and p53 activation jointly suppress HCC progression. High LINC00892 is associted with infiltration of CD8+ T cells, B cells and macrophages, and associated ...
Xu Zhang, Lina Ma, Juan Ma, Long Hai, Lina Wu, Xueyan Feng, Xiangchun Ding   +6 more
wiley   +1 more source

Interrogation of MDM2 Phosphorylation in p53 Activation Using Native Chemical Ligation: The Functional Role of Ser17 Phosphorylation in MDM2 Reexamined

, 2016
The E3 ubiquitin ligase MDM2 functions as a crucial negative regulator of the p53 tumor suppressor protein by antagonizing p53 transactivation activity and targeting p53 for degradation.
Changyou Zhan (483827), Kristen Varney (2091991), Weirong Yuan (483828), Wuyuan Lu (363836), Le Zhao (483824)   +4 more
core   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source